RXRX icon

Recursion Pharmaceuticals

6.17 USD
+0.22
3.70%
Updated Jul 30, 10:50 AM EDT
1 day
3.70%
5 days
-4.04%
1 month
21.94%
3 months
10.38%
6 months
-19.77%
Year to date
-14.42%
1 year
-22.39%
5 years
-80.29%
10 years
-80.29%
 

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Employees: 800

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

106% more repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 67

61% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 41

30% more call options, than puts

Call options by funds: $28.3M | Put options by funds: $21.7M

7% more funds holding

Funds holding: 312 [Q4 2024] → 333 (+21) [Q1 2025]

2.41% less ownership

Funds ownership: 79.42% [Q4 2024] → 77.01% (-2.41%) [Q1 2025]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]

22% less capital invested

Capital invested by funds: $2.06B [Q4 2024] → $1.61B (-$451M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
19%
downside
Avg. target
$6.50
5%
upside
High target
$8
30%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Needham
Gil Blum
30%upside
$8
Buy
Reiterated
8 Jul 2025
Morgan Stanley
Vikram Purohit
19%downside
$5
Equal-Weight
Assumed
3 Jul 2025

Financial journalist opinion

Based on 23 articles about RXRX published over the past 30 days

Neutral
Zacks Investment Research
15 hours ago
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Neutral
GlobeNewsWire
1 day ago
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST.
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Negative
The Motley Fool
1 day ago
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Clinical-stage biotech Recursion Pharmaceuticals' (RXRX -2.85%) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving them with an almost 3% decline at market close.
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Positive
24/7 Wall Street
1 day ago
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Tempus AI and Recursion Pharmaceuticals are fine ways to play the AI revolution from the health angle.
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Positive
The Motley Fool
3 days ago
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
Are Americans saving enough money to fund a comfortable retirement? Probably not.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
Positive
Benzinga
4 days ago
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
Imagine you stepped into the dimly lit hospital meeting room to pitch a new cancer‑diagnostic deal. You flick through slides powered by Palantir Technologies Inc.'s PLTR Foundry platform, showcasing data transparency and precision that would make legacy pharma pipelines look prehistoric.
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
Neutral
Zacks Investment Research
4 days ago
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Neutral
Zacks Investment Research
6 days ago
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Positive
Zacks Investment Research
6 days ago
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Negative
Benzinga
1 week ago
Top 2 Health Care Stocks You May Want To Dump This Quarter
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 2 Health Care Stocks You May Want To Dump This Quarter
Charts implemented using Lightweight Charts™